Unison Clinical Trials | Sherman Oaks, CA
Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.
Full description
This is a phase 1b, randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study of XmAb27564. It is planned to enroll approximately 48 adult patients with mild-to-severe plaque psoriasis and 80 adult patients with moderate-to-severe atopic dermatitis. All patients will receive a total of 4 doses of study drug or placebo, administered subcutaneously every 2 weeks. A one year, open-label extension is available to qualifying patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The main inclusion and exclusion criteria include, but are not limited to, the following:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
128 participants in 2 patient groups
Loading...
Central trial contact
Ralph Zitnik, MD; Seven Lueder-Powerss
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal